Quantcast
Latest Stories

New drug shows promise against rare skin cancer



WASHINGTON – A newly approved drug has shown promise in keeping two rare variations of skin cancer at bay, according to research published in the New England Journal of Medicine on Wednesday.

The drug, Erivedge (vismodegib), is made by Genentech, a US subsidiary of the Swiss drug giant Roche, and was approved by the US Food and Drug Administration in January after an expedited review.

It aims to treat basal cell carcinoma, which is the most common form of skin cancer in the world but which is rarely deadly. Basal cell carcinoma accounts for 80 percent of nonmelanoma cancers and some two million new cases in the US each year.

The journal published two studies that show how it helped some patients with two unusual variations of basal cell carcinoma: metastatic basal cell carcinoma and Gorlin syndrome, also known as Basal Cell Nevus Syndrome.

There is no other treatment for Gorlin syndrome, which strikes one in 50,000 people and involves the constant growth of tumors, which are often not deadly but can cause scarring and require frequent surgeries.

Subjects with Gorlin syndrome who took vismodegib developed an average of two new tumors per year, compared with 29 new tumors in subjects taking a placebo, the study said.

When it came to people whose basal cell carcinoma had spread, the study showed 30 percent of 33 patients with metastatic basal cell carcinoma responded to treatment, meaning their tumors shrank.

Forty-three percent of 63 subjects with locally advanced basal cell carcinoma responded in kind.

The phase II study showed a median progression-free survival time of 9.5 months, but overall survival rates have not yet been established.

“It is a landmark day for patients with basal cell carcinoma and all those involved in their care – the greatest advance in therapy yet seen for this disease,” said an accompanying editorial by John Lear, consultant dermatologist at Manchester Royal Infirmary in Britain.

However, he pointed out the high rate of adverse effects, including loss of taste, hair loss and muscle cramps, which led to a high rate of people dropping out of the study early.

“Side effects are considerable and frequent, resulting in high rates of drug discontinuation, and these rates will probably be even higher in clinical practice,” Lear said.

More study is needed to determine how long the drug may work to ward off cancer, what populations it may best serve, and when it should be optimally administered, he added.


Follow Us


Follow us on Facebook Follow on Twitter Follow on Twitter


Recent Stories:

Complete stories on our Digital Edition newsstand for tablets, netbooks and mobile phones; 14-issue free trial. About to step out? Get breaking alerts on your mobile.phone. Text ON INQ BREAKING to 4467, for Globe, Smart and Sun subscribers in the Philippines.

Tags: cancer , Health , Medicines



Copyright © 2014, .
To subscribe to the Philippine Daily Inquirer newspaper in the Philippines, call +63 2 896-6000 for Metro Manila and Metro Cebu or email your subscription request here.
Factual errors? Contact the Philippine Daily Inquirer's day desk. Believe this article violates journalistic ethics? Contact the Inquirer's Reader's Advocate. Or write The Readers' Advocate:
c/o Philippine Daily Inquirer Chino Roces Avenue corner Yague and Mascardo Streets, Makati City, Metro Manila, Philippines Or fax nos. +63 2 8974793 to 94
Advertisement
  1. How to enjoy Buntod
  2. Kim Atienza: At home with art and design
  3. Life lessons I want to teach my son
  4. No tourist draw, Malang the croc will remain wild
  5. ‘Wild West’ Masbate’s pristine marine gems
  6. The best flavors of summer in one bite, and more
  7. How Zsa Zsa Padilla found Conrad Onglao; Sharon Cuneta played Cupid
  8. Homemade yogurt, bread blended with pizza, even ramen
  9. What has happened to Barrio Fiesta and Singing Cooks & Waiters?
  10. Haneda International Airport: A destination on its own
  1. How Zsa Zsa Padilla found Conrad Onglao; Sharon Cuneta played Cupid
  2. Are your favorite malls open this Holy Week break?
  3. Historic Fort Bonifacio tunnel converted into a septic tank
  4. ‘Labahita a la bacalao’
  5. Miss America: Don’t suspend teen over prom invite
  6. How Margie Moran-Floirendo keeps her dancer’s body
  7. This is not just a farm
  8. President Quezon was born here–and so was Philippine surfing
  9. Levine designs womenswear with help from fiancee
  10. Clams and garlic, softshell crab risotto–not your usual seafood fare for Holy Week
  1. How Zsa Zsa Padilla found Conrad Onglao; Sharon Cuneta played Cupid
  2. Mary Jean Lastimosa is new Miss Universe Philippines
  3. Did Angara ruin Pia Wurtzbach’s chances at Bb. Pilipinas?
  4. Dominique–Gretchen and Tonyboy Cojuangco’s daughter–now an endorser
  5. Vinegar test helpful vs cervical cancer
  6. From Jeannie to mom of suicide victim
  7. San Vicente beaches hidden but not for long
  8. Borgy and Georgina are back; others are off–again
  9. Why is the lifestyle set now afraid to wear jewelry–before Kim Henares?
  10. Sen. Angara: I thought Pia Wurtzbach gave a good answer

News

  • Afghan hospital guard kills 3 American doctors
  • [VIDEO] No assurances on Janet Lim-Napoles’ bid to become state witness
  • South Sudan president fires long-time army leader
  • Grenade explodes outside MPD Station 1
  • 25 cops ordered relieved over links to drugs
  • Sports

  • Pacquiao can dodge tax issues
  • F1 boss Bernie Ecclestone rejects bribery charges
  • Big Chill freezes Cafe France to arrest skid
  • Pacquiao has to go through PBA Rookie draft
  • Guiao summoned by PBA for name-calling incident
  • Lifestyle

  • Gongs and southern dances star in a workshop at San Francisco Bayanihan Center
  • This woman ate what?
  • Photos explore dynamics of youths’ sexual identity
  • 12th Philippine Food Expo set at the World Trade Center
  • No tourist draw, Malang the croc will remain wild
  • Entertainment

  • Smithsonian wants photos, videos for ‘Day in the Life of Asian Pacific Americans’
  • What Garcia Marquez left behind
  • Has Ai Ai fallen deeply with ‘sireno?’
  • Sony developing live-action Barbie comedy
  • California court won’t review Jackson doctor case
  • Business

  • Metro Pacific acquires stake in Victorias
  • How ‘one percent’ economic elite was uncovered
  • Facebook profits triple as mobile soars
  • Insular Honors Sales Performers at Testimonial Rites
  • Apple increases stock buyback, will split stock
  • Technology

  • Enrile in Masters of the Universe, Lord of the Rings?
  • Top Traits of Digital Marketers
  • No truth to viral no-visa ‘chronicles’
  • ‘Unlimited’ Internet promos not really limitless; lawmakers call for probe
  • Viber releases new design for iPhone, comes to Blackberry 10 for the first time
  • Opinion

  • Editorial cartoon, April 24, 2014
  • Talking to Janet
  • Respite
  • Bucket list
  • JPII in 1981: walking a tightrope
  • Global Nation

  • Obama to visit Filipino soldiers in Fort Bonifacio
  • Fil-Am youth conferences unite under one theme
  • Embassy advisory: Filipinos still need visas to enter US
  • No travel restriction to Mideast, DFA clarifies
  • PH-HK relations repaired, but families of victims still being courted
    Marketplace